Clinical Trials
The latest news about Clinical Trials: headlines, AI summaries and the full story from every source.
- SeaStar Medical Reports 247% Year-Over-Year Revenue Growth in Q3 2026
- MiNK Therapeutics Reports Q3 2026 Financial Results and Clinical Updates
- Democratic Senators Urge HHS to Regulate Prediction Markets Linked to Clinical Trials
- Protagenic Therapeutics Announces Private Placement to Raise Up to $5 Million
- Cellectar Reports Q3 2026 Financial Results and Clinical Progress for iopofosine I-131
- Humacyte Plans November Dialysis sBLA Filing and Projects Q4 Symvess Sales Growth
- FDA Issues Not Approvable Letter for NovoCure's Optune Mya
- Hemab Therapeutics Initiates Phase III Trial for Sutacimig and Projects Cash Runway into 2029
- Senseonics Reports 140% Year-Over-Year Revenue Growth in Q3 2026
- Johnson & Johnson's Caplyta Meets Primary Endpoints in Bipolar Mania Clinical Trial
- Coherus Oncology Announces Workforce Reductions and Strategic Clinical Shift
- Xenon Pharmaceuticals Reports Q3 2026 Financial Results and Azetukalner FDA Submission
- Trevi Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Updates
- IQVIA Reports Strong Q3 2026 Results with Record Clinical Bookings and Raised Guidance
- Trevi Therapeutics Announces Clinical Trial Progress and Extended Cash Runway Through 2030
- Annexon Biosciences Reports Third Quarter GAAP EPS of -$0.25 and Updates Clinical Trial Progress
- Bicara Therapeutics Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Ocular Therapeutix Reports Q3 2026 Financial Results and AXPAXLI Regulatory Update
- Compugen Expects MAIA-Ovarian Clinical Data by Q1 2027 and Maintains Funding Through 2029
- Moderna Upgrades 2026 Revenue Guidance Following Positive Phase 3 Cancer Vaccine Results
- Wave Life Sciences Reports Strong Q3 2026 Results with Robust Cash Position and Clinical Progress
- Johnson & Johnson Experimental Immunotherapy Combination Reduces Prostate Cancer PSA Levels in Early Trial
- Amgen Develops Monthly Obesity Drug MariTide to Challenge Weekly Injection Market
- Pulse Biosciences Reports Q3 2026 Revenue Growth Driven by Vybrance Commercial Volume
- Allogene Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Updates
- Cognition Therapeutics Plans Phase III Trial for Zervimesine in DLB by Mid-2027
- Novo Nordisk CEO Provides Timeline for CagriSema Obesity Drug Launch
- Intensity Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Resumption
- Cognition Therapeutics Reports Q3 2026 Financial Results and Phase III Trial Updates
- Amylyx Pharmaceuticals Reports Positive Phase 3 LUCIDITY Trial Results and Q3 2026 Financials
- Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026
- Moderna's Ebola Vaccine Candidate Selected for WHO-Recommended Phase 2/3 Trial
- Compass Pathways to Submit FDA New Drug Application for COMP360 Within Two Weeks
- Arvinas Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine
- Immorta Bio Announces First Human Administration of SenoMune™-0257 Immunotherapy
- UBS Initiates Coverage on Viking Therapeutics with Buy Rating and $94 Price Target
- Kymera Therapeutics Reports Q3 2026 Results and Positive Phase I Data for KT-579
- StimCardio Secures $30 Million Series A Financing to Advance Wearable Atrial Fibrillation Therapy
- DBV Technologies Submits VIASKIN Peanut BLA and Reports Q3 2026 Financial Results
- ClearPoint Neuro Reports 36% Revenue Growth in Q3 2026 Driven by IRRAflow Integration
- Oncoinvent Outlines Phase III Clinical Trial Scope and Extends Cash Runway to 2027
- United Therapeutics Receives FDA Clearance for Phase 1 Trial of Treprostinil-Iloprost SMI
- Axsome Therapeutics Shows Consistent Revenue Growth Amidst Moderna's Volatility
- Wave Life Sciences Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- AbbVie Submits FDA Biologics License Application for Etentamig in Multiple Myeloma
- Bristol Myers Squibb Reports Positive Phase 3 Trial Results for Lung Cancer Drug Iza-bren
- Moderna CEO Expresses Confidence in Personalized Cancer Vaccine Expansion Beyond Melanoma
- Acumen Pharmaceuticals Reports Q3 2026 Financial Results and Awaits Alzheimer's Trial Data
- Acumen Pharmaceuticals Prepares for Phase II ALTITUDE-AD Trial Results in November